A04Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
Kim, D., Tiseo, M., Ahn, M., Reckamp, K., Holmskov Hansen, K., Kim, S., Huber, R., West, H., Groen, H., Hochmair, M., Leighl, N., Gettinger, S., Langer, C., Paz-Ares Rodriguez, L., Smit, E., ReichmannVolume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw332.04
Date:
September, 2016
File:
PDF, 67 KB
english, 2016